Entest BioMedical's Zander Therapeutics Unit Files Patent Application on Ex Vivo Activated Autologous Immune Cells

Aug 11, 2015, 08:30 ET from Entest BioMedical Inc.

SAN DIEGO, Aug. 11, 2015 /PRNewswire/ -- Entest BioMedical Inc.'s (OTC: ENTBD) Zander Therapeutics unit announced today its personalized canine cancer immune therapy platform and proof-of-concept experimental data.  The data on which this provisional patent was based came from previous research conducted by Thomas Ichim, PhD, a scientific consultant to Zander.  On July 31, 2015, Zander filed a provisional patent application with the United States Patent Office (USPTO) on intellectual property in the veterinary oncology space. 

The US application # 62199256, entitled "Cancer therapy by ex vivo activated autologous immune cells" covers methods of activating blood cells from cancer patients outside of the body, and "reprogramming" the cells to attack the cancer once re-administered to the same patient.  Zander collaborators were able to apply the process described in the patent application to canine cells, and demonstrate in vitro activation of the immune cells to kill canine lymphoma cells in vitro.

"In the area of human oncology, the use of the immune system to kill cancer cells is being heralded as the "Breakthrough of the Year"[1], unfortunately in many situations translation from human medicine to veterinary medicine is lagging in years or in some cases decades," said Dr. Thomas Ichim, a scientific consultant to Zander Therapeutics, "The successful demonstration that concepts we developed in human systems can be applied to dogs, provides strong incentive for us to initiate canine studies, with the intention of pursuing commercialization in the veterinary space."

Zander's proprietary approach to inducing immune system cells to kill cancer involves extraction of a small amount of blood (10 ml), purifying from the blood dendritic cells and lymphocytes, and growing the cells together with proprietary proteins termed cytokines, which endows a specific type of lymphocyte, termed the NK cell, to kill tumor cells.  The Zander model in development calls for veterinarians to ship blood to a processing facility, with the cellular product being generated within 2 weeks, and the product shipped back for the veterinarian to re-infusion. 

[1] https://www.sciencemag.org/content/342/6165/1432.full

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTC PINK: ENTBD) is a developer of veterinary medicines that harness the animal's own reparative / immunological mechanisms. The Company, through its Zander Therapeutics unit, is also pursuing cancer therapeutics for veterinary application.  Zander Therapeutics Inc. is developing small molecule and cancer stem cell therapies for treating Feline Leukemia and Canine Cancer.  Zander is a wholly owned subsidiary of Entest BioMedical Inc.


This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

David R. Koos
Chairman & CEO
Entest BioMedical Inc.
+1-619-702-1404 phone
+1-619-330-2328 fax


SOURCE Entest BioMedical Inc.